The IDMC has NOT met this year, otherwise there would have been a related announcement. It makes no sense for the IDMC to meet until there have been 95 confirmed events AND Covance has fully documented each case.
I expect the next meeting of the IDMC to coincide with the Interim Analysis, which should take place well before May.
I do not expect the company to publish results of the analysis as it may be involved in delicate negotiations with the FDA at the time. The company will, however, be able to reveal the results to potential Licensees under strict confidentially provisions. If you read an announcement that the IDMC has met and (presumably) authorizes continuation of the trial, this should mean that the Interim Analysis has been conducted.
This puts into context a recent announcement by Novogen that executive salaries had been cut by 20% and eleven staff let go from their non-oncology workforce. I believe this is simply a case of prudent cost control in a difficult environment. Everything else appears to be going as planned.
NRT Price at posting:
62.2¢ Sentiment: ST Buy Disclosure: Held
